IA
AVIR icon

IFP Advisors’s Atea Pharmaceuticals AVIR Stock Holding History

IFP Advisors’s Portfolio AVIR Stock Details AVIR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$339 Buy
73
+69
+1,725% +$343 ﹤0.01% 4757
2026
Q1 		$22 Hold
4
– – ﹤0.01% 4910
2025
Q4 		$14 Buy
4
+1
+33% +$3 ﹤0.01% 4822
2025
Q3 		$9 Buy
+3
New +$10 ﹤0.01% 4786
2025
Q2 		– Hold
0
– – – 4381
2025
Q1 		– Hold
0
– – – 4014
2024
Q4 		– Hold
0
– – – 4217

Other funds holding AVIR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
BCM
BML Capital Management Zionsville, Indiana $176M AUM 123.21% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $2.2B AUM 156.35% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

IFP Advisors's AVIR Position: Q2 2026 in Review

IFP Advisors increased its Atea Pharmaceuticals (AVIR) stake by 1,725% in Q2 2026, buying an estimated $343 and bringing the position to 73 shares worth $339. The position accounts for ﹤0.01% of the portfolio, ranked #4757.

IFP Advisors first reported a position in AVIR in Q3 2025 and has held it in 4 quarters since. 124 funds tracked by Wall St. Rank hold AVIR as of Q2 2026.

  • IFP Advisors held 73 shares of Atea Pharmaceuticals worth $339 as of Q2 2026.
  • IFP Advisors bought 69 Atea Pharmaceuticals shares in Q2 2026, an estimated $343.
  • Atea Pharmaceuticals made up ﹤0.01% of IFP Advisors's portfolio in Q2 2026, its #4757 holding.
  • IFP Advisors first reported a position in Atea Pharmaceuticals in Q3 2025 and has held it in 4 quarters since.
  • 124 funds tracked by Wall St. Rank held Atea Pharmaceuticals as of Q2 2026.

Based on IFP Advisors's 13F filing for Q2 2026, filed 20 Jul 2026.